MLL
BMRN icon

Moody Lynn & Lieberson’s BioMarin Pharmaceuticals BMRN Stock Holding History

Moody Lynn & Lieberson’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,850
Closed -$812K – 222
2022
Q4 		$812K Buy
+7,850
New +$737K 0.07% 122

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Moody Lynn & Lieberson's BMRN Position: Q1 2023 in Review

Moody Lynn & Lieberson sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 7,850 shares — an estimated $812K sold.

Moody Lynn & Lieberson first reported a position in BMRN in Q4 2022 and held it in 1 quarter. The position peaked at $812K in Q4 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • Moody Lynn & Lieberson reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 7,850 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $812K.
  • Moody Lynn & Lieberson first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Moody Lynn & Lieberson's BioMarin Pharmaceuticals position peaked at $812K in Q4 2022.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Moody Lynn & Lieberson's 13F filing for Q1 2023, filed 2 May 2023.